Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

CAMBRIDGE, Mass., Dec. 14, 2023 -- Cullinan Oncology, Inc. , a bi...

Related Keywords

Chad ,Cambridge ,Cambridgeshire ,United Kingdom ,Jeffrey Jones ,Rose Weldon ,Exchange Commission ,Linkedin ,Twitter ,Nasdaq ,Cullinan Oncology Inc ,Chief Medical Officer ,Cullinan Oncology ,Private Securities Litigation Reform Act ,Annual Report ,Markets ,